Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda, a biotech startup that uses AI to discover new drugs in the natural world, has raised a $311 million Series E at a $2 billion valuation. The fresh funding, which was led by Catalio Capital Man...










